ASP1517 Phase 3 Clinical Trial -A Multi-center, Open-label Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 31 Oct 2017 Top-line results presented in an Astellas Pharma media release.
- 09 Aug 2017 Status changed from active, no longer recruiting to completed.
- 14 Apr 2017 Planned End Date changed from 1 Jun 2017 to 30 Sep 2017.